Study of radium-223 dichloride versus placebo and hormonal treatment as background therapy in subjects with bone predominant HER2 negative hormone receptor positive metastatic breast cancer

Update Il y a 4 ans
Reference: EUCTR2014-002113-39

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To assess the efficacy and safety of radium-223 dichloride in subjects with HER2 negative, hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy.


Inclusion criteria

  • HER2 negative hormone receptor positive metastatic breast cancer with bone metastases treated with standard of care hormonal treatment